2014
DOI: 10.1371/journal.pone.0098426 View full text |Buy / Rent full text
|
|

Abstract: BackgroundA Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group.MethodsCitAD was a randomized, double-masked, placebo-controlled, multicenter clinical trial for agitation in Alzheimer's disease (AD). Participants were assigned to citalopram (target dose of 30 mg/day) or placebo in a 1∶1 ratio. 186 peopl… Show more

Help me understand this report

Search citation statements

Order By: Relevance
0
0
0
0
0
1
28
0
3

Publication Types

Select...

Relationship

0
0

Authors

Journals